- Home
- NAGE vs TCPC Comparison
NAGE vs TCPC Comparison
Compare NAGE & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAGE | TCPC |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | 117 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.2M | 308.8M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | NAGE | TCPC |
|---|---|---|
| Price | $3.36 | $3.23 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 3 | 2 |
| Target Price | ★ $16.00 | $3.50 |
| AVG Volume (30 Days) | 667.9K | ★ 919.1K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 18.23% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.51 | N/A |
| Revenue Next Year | $14.58 | N/A |
| P/E Ratio | $21.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.29 | $3.08 |
| 52 Week High | $14.66 | $7.92 |
Technical Indicators
Market Signals| Indicator | NAGE | TCPC |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 30.66 |
| Support Level | $3.35 | N/A |
| Resistance Level | $4.04 | $3.75 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 37.74 | 20.27 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About TCPC BlackRock TCP Capital Corp.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.